HBM4003

DRUG2 trials

Sponsors

Harbour BioMed US, Inc., Harbour BioMed (Guangzhou) Co. Ltd.

Conditions

Advanced Solid TumorCRCNeuroendocrine TumorsSolid Tumors

Phase 1

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

CompletedNCT04135261

Harbour BioMed US, Inc.Advanced Solid Tumor

Start: 2019-09-24End: 2023-02-15Updated: 2023-04-18

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Active, not recruitingNCT05167071

Harbour BioMed (Guangzhou) Co. Ltd.CRC, Neuroendocrine Tumors, Solid Tumors

Start: 2021-12-28End: 2026-06-30Updated: 2025-04-27

Related Papers

Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study.

2025-06-03

Abstract CT263: A phase Ib dose-expansion study of porustobart, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with advanced high-grade neuroendocrine neoplasms (NENs)

Cancer Research2023-04-141 citations

A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-013 citations